Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Trials

MRD trials

The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov set of studies that are recruiting or not yet recruiting. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.

Recruiting and not-yet-recruiting studies that use ctDNA, cfDNA, or MRD in eligibility, a treatment decision, or a primary or secondary endpoint, plus observational studies focused on that testing. 1123 studies from 2267 registry records. Hematologic trials that list MRD only as a secondary endpoint are listed separately. Last synced Nov 18, 2026, 2:04 PM EST.

  • GU · Bladder / urothelialRecruitingPhase 2 / Phase 3NCT05987241

    Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

    National Cancer Institute (NCI) · 505 locations · Updated 2026-11-12

  • GU · Bladder / urothelialRecruitingPhase 3NCT07097142

    Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

    NRG Oncology · 259 locations · Updated 2026-10-23

  • GU · Bladder / urothelialNot yet recruitingPhase 3NCT07346053

    The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer

    Guliz Ozgun · 5 locations · Updated 2026-10-01

  • GU · Bladder / urothelialRecruitingPhase 3NCT07067749

    Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer

    University of Rome Tor Vergata · 1 locations · Updated 2025-07-24

  • GU · Bladder / urothelialNot yet recruitingPhase 2NCT07946601

    Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy

    Case Comprehensive Cancer Center · 1 locations · Updated 2026-11-18

  • GU · Bladder / urothelialRecruitingPhase 2NCT07908979

    Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer

    Fox Chase Cancer Center · 1 locations · Updated 2026-11-02

  • GU · Bladder / urothelialRecruitingPhase 2NCT07625527

    Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

    Tianjin Medical University Second Hospital · 4 locations · Updated 2026-10-15

  • GU · Bladder / urothelialRecruitingPhase 2NCT07048457

    Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma

    Yale University · 2 locations · Updated 2026-10-07

  • GU · Bladder / urothelialNot yet recruitingPhase 2NCT07822373

    A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer

    University of Utah · 1 locations · Updated 2026-09-16

  • GU · Bladder / urothelialNot yet recruitingPhase 2NCT07643519

    Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma

    University of Florida · Locations not reported · Updated 2026-09-14

  • GU · Bladder / urothelialNot yet recruitingPhase 2NCT07663747

    Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC

    The Netherlands Cancer Institute · 3 locations · Updated 2026-06-25

  • GU · Bladder / urothelialRecruitingPhase 2NCT07475403

    Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

    Tianjin Medical University Second Hospital · 3 locations · Updated 2026-05-26

  • GU · Bladder / urothelialRecruitingPhase 2NCT06682728

    Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

    University of California, Irvine · 1 locations · Updated 2026-04-30

  • GU · Bladder / urothelialRecruitingPhase 2NCT07183319

    Circulating Tumor DNA Response In Urothelial Cancer

    University of Oklahoma · 1 locations · Updated 2026-02-02

  • GU · Bladder / urothelialNot yet recruitingPhase 2NCT07142200

    A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection

    RenJi Hospital · 1 locations · Updated 2025-08-26

  • GU · Bladder / urothelialNot yet recruitingPhase 2NCT06528483

    Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer

    Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · 1 locations · Updated 2024-07-30

  • GU · Bladder / urothelialRecruitingNot applicableNCT07187635

    Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer

    Tianjin Medical University Second Hospital · 7 locations · Updated 2026-11-03

  • GU · Bladder / urothelialRecruitingNot reportedObservationalNCT06396533

    Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)

    Fox Chase Cancer Center · 2 locations · Updated 2026-11-02

  • GU · Bladder / urothelialNot yet recruitingNot reportedObservationalNCT07793240

    Circulating Tumor DNA (ctDNA) in High Grade Upper Tract Urothelial Cancer (UTUC)

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 1 locations · Updated 2026-10-29

  • GU · Bladder / urothelialNot yet recruitingNot reportedObservationalNCT07893509

    Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC)

    Bladder Cancer Advocacy Network · 1 locations · Updated 2026-10-26

  • GU · Bladder / urothelialRecruitingNot reportedObservationalNCT07888374

    Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification

    Ruijin Hospital · 1 locations · Updated 2026-10-22

  • GU · Bladder / urothelialRecruitingNot reportedObservationalNCT07726602

    Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial

    OHSU Knight Cancer Institute · 1 locations · Updated 2026-08-14

  • GU · Bladder / urothelialRecruitingNot reportedObservationalNCT07756437

    Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer

    AZ Sint-Lucas Gent · 1 locations · Updated 2026-08-10

  • GU · Bladder / urothelialRecruitingNot reportedObservationalNCT07581496

    T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer

    University Hospital, Basel, Switzerland · 2 locations · Updated 2026-05-18

  • GU · Prostate, Bladder / urothelialNot yet recruitingNot reportedObservationalNCT07468838

    Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder Cancer

    Institut Cancerologie de l'Ouest · Locations not reported · Updated 2026-03-16

  • GU · Bladder / urothelialRecruitingNot reportedObservationalNCT07452432

    Korean Prospective Upper Tract Urothelial Carcinoma Cohort

    Samsung Medical Center · 1 locations · Updated 2026-03-05

  • GU · Bladder / urothelialRecruitingNot reportedObservationalNCT07130578

    The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer

    Tianjin Medical University Second Hospital · 2 locations · Updated 2026-03-03

  • GU · Bladder / urothelialRecruitingNot reportedObservationalNCT07441499

    Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma

    Tianjin Medical University Second Hospital · 1 locations · Updated 2026-03-02

  • GU · Bladder / urothelialRecruitingNot reportedObservationalNCT05595408

    Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma

    RenJi Hospital · 1 locations · Updated 2025-12-09

  • GU · Bladder / urothelialRecruitingNot reportedObservationalNCT06310759

    Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer

    Tampere University Hospital · 8 locations · Updated 2025-10-10

  • GU · Kidney / RCC, Prostate, Bladder / urothelialRecruitingNot reportedObservationalNCT04197414

    Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA

    Yonsei University · 1 locations · Updated 2019-12-13

Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.